 The recent advancement of so-called non-invasive prenatal testing (NIPT) has complicated existing ethical issues and introduced new ones in obstetrical care, and some believe that current normative frameworks for assessing prenatal testing are ill-equipped to navigate these issues (Schmitz 2013). The past decade has seen enormous changes in testing technologies, and non-invasive prenatal testing is a striking example of how rapidly new testing methods translate to clinical and commercial enterprise (Skirton and Patch 2013). Most NIPT targets aneuploidy; some tests for monegenic disorders are also sought after but development and clinical uptake of these is relatively slow (Chitty and Bianchi 2013).